232 related articles for article (PubMed ID: 29132121)
1. The therapeutic potential of CFTR modulators for COPD and other airway diseases.
Solomon GM; Fu L; Rowe SM; Collawn JF
Curr Opin Pharmacol; 2017 Jun; 34():132-139. PubMed ID: 29132121
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Approaches to Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction in Chronic Bronchitis.
Solomon GM; Raju SV; Dransfield MT; Rowe SM
Ann Am Thorac Soc; 2016 Apr; 13 Suppl 2(Suppl 2):S169-76. PubMed ID: 27115953
[TBL] [Abstract][Full Text] [Related]
3. CFTR dysfunction in cystic fibrosis and chronic obstructive pulmonary disease.
Fernandez Fernandez E; De Santi C; De Rose V; Greene CM
Expert Rev Respir Med; 2018 Jun; 12(6):483-492. PubMed ID: 29750581
[TBL] [Abstract][Full Text] [Related]
4. Cigarette Smoke-Induced Acquired Dysfunction of Cystic Fibrosis Transmembrane Conductance Regulator in the Pathogenesis of Chronic Obstructive Pulmonary Disease.
Shi J; Li H; Yuan C; Luo M; Wei J; Liu X
Oxid Med Cell Longev; 2018; 2018():6567578. PubMed ID: 29849907
[TBL] [Abstract][Full Text] [Related]
5. Cystic Fibrosis Transmembrane Conductance Regulator. Implications in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.
Cantin AM
Ann Am Thorac Soc; 2016 Apr; 13 Suppl 2():S150-5. PubMed ID: 27115950
[TBL] [Abstract][Full Text] [Related]
6. CFTR targeted therapies: recent advances in cystic fibrosis and possibilities in other diseases of the airways.
Patel SD; Bono TR; Rowe SM; Solomon GM
Eur Respir Rev; 2020 Jun; 29(156):. PubMed ID: 32554756
[TBL] [Abstract][Full Text] [Related]
7. Unplugging Mucus in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.
Mall MA
Ann Am Thorac Soc; 2016 Apr; 13 Suppl 2():S177-85. PubMed ID: 27115954
[TBL] [Abstract][Full Text] [Related]
8. Cigarette smoke and CFTR: implications in the pathogenesis of COPD.
Rab A; Rowe SM; Raju SV; Bebok Z; Matalon S; Collawn JF
Am J Physiol Lung Cell Mol Physiol; 2013 Oct; 305(8):L530-41. PubMed ID: 23934925
[TBL] [Abstract][Full Text] [Related]
9. Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction in Chronic Bronchitis and Other Diseases of Mucus Clearance.
Raju SV; Solomon GM; Dransfield MT; Rowe SM
Clin Chest Med; 2016 Mar; 37(1):147-58. PubMed ID: 26857776
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a novel CFTR potentiator in COPD ferrets with acquired CFTR dysfunction.
Kaza N; Lin VY; Stanford D; Hussain SS; Falk Libby E; Kim H; Borgonovi M; Conrath K; Mutyam V; Byzek SA; Tang LP; Trombley JE; Rasmussen L; Schoeb T; Leung HM; Tearney GJ; Raju SV; Rowe SM
Eur Respir J; 2022 Jul; 60(1):. PubMed ID: 34916262
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-17 Pathophysiology and Therapeutic Intervention in Cystic Fibrosis Lung Infection and Inflammation.
Hsu D; Taylor P; Fletcher D; van Heeckeren R; Eastman J; van Heeckeren A; Davis P; Chmiel JF; Pearlman E; Bonfield TL
Infect Immun; 2016 Sep; 84(9):2410-21. PubMed ID: 27271746
[TBL] [Abstract][Full Text] [Related]
12. Acquired cystic fibrosis transmembrane conductance regulator dysfunction in the lower airways in COPD.
Dransfield MT; Wilhelm AM; Flanagan B; Courville C; Tidwell SL; Raju SV; Gaggar A; Steele C; Tang LP; Liu B; Rowe SM
Chest; 2013 Aug; 144(2):498-506. PubMed ID: 23538783
[TBL] [Abstract][Full Text] [Related]
13. Control of the proinflammatory state in cystic fibrosis lung epithelial cells by genes from the TNF-alphaR/NFkappaB pathway.
Eidelman O; Srivastava M; Zhang J; Leighton X; Murtie J; Jozwik C; Jacobson K; Weinstein DL; Metcalf EL; Pollard HB
Mol Med; 2001 Aug; 7(8):523-34. PubMed ID: 11591888
[TBL] [Abstract][Full Text] [Related]
14. Potential systemic effects of acquired CFTR dysfunction in COPD.
Miravitlles M; Criner GJ; Mall MA; Rowe SM; Vogelmeier CF; Hederer B; Schoenberger M; Altman P
Respir Med; 2024 Jan; 221():107499. PubMed ID: 38104786
[TBL] [Abstract][Full Text] [Related]
15. New and emerging therapies for pulmonary complications of cystic fibrosis.
Tonelli MR; Aitken ML
Drugs; 2001; 61(10):1379-85. PubMed ID: 11558827
[TBL] [Abstract][Full Text] [Related]
16. CFTR: cystic fibrosis and beyond.
Mall MA; Hartl D
Eur Respir J; 2014 Oct; 44(4):1042-54. PubMed ID: 24925916
[TBL] [Abstract][Full Text] [Related]
17. Augmentation of S-Nitrosoglutathione Controls Cigarette Smoke-Induced Inflammatory-Oxidative Stress and Chronic Obstructive Pulmonary Disease-Emphysema Pathogenesis by Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function.
Bodas M; Silverberg D; Walworth K; Brucia K; Vij N
Antioxid Redox Signal; 2017 Sep; 27(7):433-451. PubMed ID: 28006950
[TBL] [Abstract][Full Text] [Related]
18. Dynamic activation of cystic fibrosis transmembrane conductance regulator by type 3 and type 4D phosphodiesterase inhibitors.
Liu S; Veilleux A; Zhang L; Young A; Kwok E; Laliberté F; Chung C; Tota MR; Dubé D; Friesen RW; Huang Z
J Pharmacol Exp Ther; 2005 Aug; 314(2):846-54. PubMed ID: 15901792
[TBL] [Abstract][Full Text] [Related]
19. Improvement of defective cystic fibrosis airway epithelial wound repair after CFTR rescue.
Trinh NT; Bardou O; Privé A; Maillé E; Adam D; Lingée S; Ferraro P; Desrosiers MY; Coraux C; Brochiero E
Eur Respir J; 2012 Dec; 40(6):1390-400. PubMed ID: 22496330
[TBL] [Abstract][Full Text] [Related]
20. Roflumilast reverses CFTR-mediated ion transport dysfunction in cigarette smoke-exposed mice.
Raju SV; Rasmussen L; Sloane PA; Tang LP; Libby EF; Rowe SM
Respir Res; 2017 Sep; 18(1):173. PubMed ID: 28923049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
